Therefore, systematic research to maximize effectiveness while minimizing side effects of anti-VEGF therapy in ROP is still needed, as dose, duration of action, and molecular entity of anti-VEGF need to be considered. The gene discussed is VEGFA; the disease is retinopathy of prematurity.